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ation to areas of potential residual microscopic disease while minimizing doses to normal tissues.
IORT using high-dose-rate (HDR) brachytherapy allows dose modulation and delivery of concom-
itant boosts to high-risk areas. This study describes a novel technique of HDR-IORT with dose
painting (DP) (HDR-IORT-DP) and evaluates the clinical outcomes.
METHODS AND MATERIALS: Sixteen patients with recurrent cancers received HDR-IORT-
DP at the time of radical resection. Of these patients, 13 had colorectal cancer, 2 had head and neck
cancer, and 1 had a gynecologic malignancy. All received external beam radiation previously. Nega-
tive margin (R0) was obtained in 12 patients (75%) and microscopically positive margins (R1) in 4
patients (25%).
RESULTS: The median total target and boost area were 45 and 8.5 cm2, and HDR-IORT and boost
dose were 1500 and 1750 cGy, respectively. Median followup was 14.9 months. The 2-year local
control and overall survival were 80% and 20%, respectively. Eleven patients (69%) developed
distant metastasis and were deceased at the time of the last followup. A total of 13 patients
(19%) developed Grade 3 toxicity related to HDR-IORT; no grade 4þ toxicities were observed.
CONCLUSIONS: HDR-IORT-DP technique is feasible, safe, and allows for dose escalation in
locally advanced or recurrent previously irradiated tumors. To our knowledge, this is the first clin-
ical report on HDR-IORT-DP. Further studies are warranted to evaluate efficacy in a larger patient
cohort. Local control was encouraging in our patients.  2013 American Brachytherapy Society.
Published by Elsevier Inc. All rights reserved.Keywords: Intraoperative radiotherapy; High-dose-rate brachytherapy; Reirradiation; Dose paintingIntroduction
Management of recurrent neoplasms remains a clinical
challenge. Despite aggressive surgery, chemotherapy, and/
or radiotherapy, locally advanced cancers recur in
15e50% of patients (1). Locoregional relapse after resec-
tion of colorectal cancer is associated with poor prognosis,
with median survival of 11e15 months, and often as few as
5% of patients survive 5 years (2). Intraoperative radio-
therapy (IORT) has been advocated (3) as a componentber 2011; received in revised form 21 March 2012;
2.
no financial disclosures or conflicts of interests.
uthor. Department of Radiation Oncology, Memorial
cer Center, 1275 York Avenue, New York, NY
9-3983; fax: 212-639-2417.
oodmank@mskcc.org (K.A. Goodman).
nt matter  2013 American Brachytherapy Society. Publis
.1016/j.brachy.2012.04.011of an aggressive multidisciplinary management in T4 or
recurrent tumors. It seems to provide improvement in tumor
local control (LC), while limiting dose to normal adjacent
structures and minimizing toxicity; this has been the ratio-
nale for its use. It is given as a single fraction with doses
ranging from 10 to 20 Gy, which has been estimated to
have the cell-killing equivalence of two to three times the
dose using conventional external beam radiotherapy
(EBRT) (3).
IORT can be delivered by several different techniques:
electron beam therapy, orthovoltage radiotherapy, and
high-dose-rate (HDR) brachytherapy. Most centers use in-
traoperative electron radiotherapy (IOERT) where the radi-
ation is delivered by a linear accelerator thorough a rigid
cone directed to the tumor bed. For HDR brachytherapy
technique, a flexible applicator is placed in direct contact
to the area to be treated and source guide tubes arehed by Elsevier Inc. All rights reserved.
2 L.K. Morikawa et al. / Brachytherapy 12 (2013) 1e7connected to an afterloader system to deliver the radiation
via a 192Ir source.
At our institution, IORT is delivered with HDR brachy-
therapy using the HarrisoneAndersoneMick (HAM) appli-
cator (Mick Radio-Nuclear Instruments, Inc., NY) that
allows a very conformal treatment even on curved and deep
body surfaces (4). The use of HDR-IORT is also ideal in
particular sites, such as the lateral pelvic sidewall or deep
in the pelvis, as well as in pediatric patients, where an elec-
tron rigid cone could be relatively inaccessible. Usually,
a square/rectangular area is treated. This multiple-channel
applicator and the use of computerized treatment planning
systems allow for dose optimization by varying source
positions and dwell times. The dose can be sculpted inside
of the target area permitting dose escalation or de-
escalation, allowing for planned nonhomogenous dose
distributions or dose painting (DP). This DP technique
allows the sites highly suspicious for positive microscopic
disease or close margins to be treated to higher doses, while
minimizing dose to areas of subclinical spread; normal
organs could also be more effectively spared from high or
unnecessary doses of radiation.
To our knowledge, this is the first clinical report on
HDR-IORT using a DP technique (HDR-IORT-DP). The
aim of this study is to describe the HDR-IORT-DP tech-
nique and report on the preliminary clinical outcomes of
patients treated with this approach.Table 1
Patient and dosimetric characteristics
Age, y 62.5 (24e85)
Gender
Male 10
Female 6
Type of cancer
Colorectal 13
Head and neck 2
Gynecologic 1
Margin
R0 12
R1 4
Total area treated (cm2) 45 (8e136)
Boost area (cm2) 8.5 (4e42)
Number of channels 7 (3e18)
Number of dwell positions 9 (7e13)
Treatment time (min) 36.5 (12e98)
Dose 1 (cGy) 1500 (1250e1750)
Dose 2 (cGy) 1750 (1750e1850)Methods and materials
Beginning in 2007, the DP technique was introduced for
HDR-IORT cases at Memorial SloaneKettering Cancer
Center; thus the treatment plans for all patients who
received IORT after January 2007 were reviewed to identify
IORT plans using DP. A total of 207 patients with locally
advanced or recurrent neoplasms, who underwent IORT
between January 12, 2007 and August 25, 2010 were iden-
tified. Among this group, 16 patients (7.7%) received HDR-
IORT-DP and comprised our study group: 13 patients had
recurrent colorectal cancer, 2 patients had recurrent cancer
of the head and neck region, and 1 had a gynecologic
malignancy. All patients in this group had undergone
surgical resection and EBRT previously and had areas
within the field that were identified by the surgeon to be
at higher risk of microscopic residual disease or were adja-
cent to critical structures such as the ureter, where adequate
shielding could not be achieved owing to geometric
constraints. DP was indicated in these cases to either
achieve modulation of the dose and delivery of a concomi-
tant boost to higher-risk areas within the resection bed,
while delivering a lower dose to the regions closest to
normal structures or to achieve even more conformal
dosimetry to a more complicated geometric region within
the square or rectangular treatment region created by the
HAM applicator. At the time of HDR-IORT-DP, patientswere undergoing radical resection with expected close
margins owing to locally advanced/recurrent nature of the
tumors. Final resection margins were negative (R0) in 12
patients (75%) and microscopically positive margins (R1)
in 4 patients (25%). Patient and treatment characteristics
are shown in Table 1.
The HDR-IORT-DP was delivered using the HAM appli-
cator, a flexible pad of silicone rubber that has 8-mm thick-
ness and 22 cm in length (Fig. 1). Multiple catheters (3e24)
are embedded parallel to each other spaced 10-mm apart,
while a fixed source-to-tissue distance of 5 mm is main-
tained. All procedures were performed in a dedicated
shielded operating room. The HDR-IORT-DP technique
can be summarized as follows: After tumor resection, the
decision to proceed with IORT is based on the radiation
oncologist’s and the surgeon’s impression of the risk for
close or microscopically positive margins. If deemed neces-
sary, the area at risk is mapped out by the surgeon and radi-
ation oncologist, and the HAM applicator is chosen with the
number of channels to cover the target area appropriately. A
sterile, transparent, and flexible template that mimics the
HAM applicator and varies in number of channels from 3
to 24 is used to define the ‘‘DP’’ regions within the treatment
area (Fig. 2). The region for dose escalation and/or de-
escalation is demarcated by the radiation oncologist using
a surgical pen. The same template is also used when changes
in the shape of the radiation field are desired. The template
containing this information is given to the physicist to incor-
porate within the intraoperative treatment planning system.
The orientation of the applicator and the template must be
established to implement such dose prescriptions correctly.
The dose to a larger area (Dose 1) and to the boost region
(Dose 2) is determined by the radiation oncologist and
prescribed to 0.5 cm from the applicator’s surface. The
HAM applicator is positioned in direct contact with the area
at risk using either sutures or packing to hold the applicator
in place (Fig. 3a). Packing is also used to displace normal
Fig. 1. HarrisoneAndersoneMick applicator.
3L.K. Morikawa et al. / Brachytherapy 12 (2013) 1e7adjacent organs (e.g., large bowel, bladder, and small intes-
tines) away from the field, as well as lead shields to reduce
the dose to normal structures in close contact with the appli-
cator (Fig. 3b). The HAM applicator catheters are then con-
nected to the HDR machine (Fig. 4), the staff leaves the
room, and the patient is prepared for treatment via remote
afterloader control. Treatment planning is performed while
the applicator is secured in the treatment position using
the Abacus HDR planning software (GammaMed, Inc.,
North Jackson, OH). It is especially efficient for planning
treatments using applicators with fixed or predefined geom-
etry as it allows the import of the implant geometry. SuchFig. 2. Template for high-dose-rate intraoperative radiation therapy with
dose painting.a program was developed in-house to interface with Abacus
and transfer the treatment geometry as defined in the oper-
ating room. The treatment geometry includes source stop-
ping positions and dose reference points, required for
dwell-time optimization. A secondary dose calculation algo-
rithm for quality assurance of HDR treatment planning is
also performed (5, 6). Figure 5 shows a coronal view of dose
distribution using the DP for dose-escalation and also dose
distribution in an irregular field. After the plan is evaluated
and approved by the physician, a second physicist performs
an independent check of the treatment plan. The process of
planning and checking the plan has been streamlined and
takes approximately 5 min. Once the plan is checked and
approved, the treatment proceeds and patient vital signs
are monitored remotely.
All patients in this study were followed by the surgeon
and/or radiation oncologist at 3- to 6-month intervals. All
information related to clinical outcome was obtained from
the patient electronic medical record system. This was
a retrospective study approved by the Institutional Review
Board.
Treatment-related complications were classified using
the Common Toxicity Criteria of Adverse Effects version
3.0. Overall survival (OS) and LC rates were calculated
by the KaplaneMeier method. Local failure was defined
as recurrent disease inside of the IORT field and distant
failure included any extra-IORT site described by the
physician on physical examination, radiographic, and/or
pathologic findings.Results
The median total target and boost area were 45 and
8.5 cm2, respectively. The median Dose 1 and 2 (boost)
were 1500 cGy (range, 1250e1750 cGy) and 1750 cGy
(range, 1750e1850 cGy), respectively. In all cases, the
dose was prescribed to 0.5-cm depth from the applicator
surface. The median treatment time was 36.5 min (range,
12e98 min). The median followup was 14.9 months (range,
1e41 months) and OS was 17.5 months (range, 6e34
months). The 2-year actuarial LC and OS for all patients
were 80% and 20%, respectively (Figs. 6a and 6b). Eleven
patients (68.7%) developed distant metastasis (DM) and
had died owing to the progression of disease at the time
of last followup.
Among the 4 patients who had an R1 resection, 3 died of
DM disease (75%) and 2 (50%) had evidence of local
recurrence. None of the patients who underwent an R0
resection had a definitive local recurrence as of the time
of last followup or death.
IORT-specific complications were identified by any
description in the medical record of sign or symptom that
could specifically be related to previous radiation treat-
ment. Three patients (19%) developed toxicity Grade 3
described as ‘‘related to HDR-IORT.’’ All of them also
Fig. 3. (a) HarrisoneAndersoneMick (HAM) applicator in place. (b) Packing to displace normal organs away and to keep HAM applicator in place.
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ureteral stricture requiring nephrostomy and stent place-
ment. The second patient developed a pelvic abscess and
ileal pouch/colonic fistula and a third patient developed
a rectovaginal fistula. No Grade 4 or 5 toxicity was
identified.Discussion
Local failure after combined modality therapy remains
a clinical challenge for many types of cancer, as further
local options are often limited owing to postoperative and
postradiation fibrosis and adhesions, the absence of intact
fascial planes, and highly infiltrative disease. Systemic
therapy may also be less effective in the setting of prior
surgery and radiotherapy owing to poor vascular supply
to the irradiated postoperative bed. Locally recurrent malig-
nancies can cause severe pain owing to compression or
nerve involvement, bleeding, or obstruction of adjacent
structures such as gastrointestinal or urinary tract. Retreat-
ment using EBRT is limited by dose constraints forFig. 4. HarrisoneAndersoneMick applicator connected to high-dose-rate
machine.previously treated normal tissue adjacent to the tumor
bed. Surgical resection of a recurrent tumor in a previously
irradiated field may be very challenging and outcomes have
historically been poor, with 5-year survival rates of 0% for
patients undergoing surgery alone for pelvic recurrence
from rectal cancer (3). Thus, at most institutions, patients
are treated with palliative intent; however, this subset of
patients should be considered for salvage treatment using
a multimodality approach. Radical resection with IORT
has the advantage of delivering tumoricidal doses of radia-
tion to areas with very high risk for local failure, while
minimizing the dose to adjacent normal organs (7, 8).
The DP technique adds additional flexibility in deliv-
ering HDR-IORT to complex, deep, and previously irradi-
ated areas, especially in recurrent colorectal tumors. The
technique described in our study allows for HDR-IORT
delivery to almost any complex area or anatomy because
dose can be optimized and treatment field can be modulated
to achieve ideal geometric coverage. Not only suspicious
areas for microscopic disease can be boosted but also crit-
ical normal structures such as bowel, nerves, and ureters
can be protected from unnecessary radiation. The DP
expands the limitation of the retangular HAM applicator
and makes it possible to create more geometrically complex
treatment areas. However, this entails the use of a template
to delineate the target area as well as more complex treat-
ment planning, which could potentially result in a slightly
lengthened procedure; thus, one should carefully identify
the ideal candidate to use this nonuniform HDR-IORT tech-
nique. Finally, another drawback of this more complicated
approach is that there is a greater potential for error
regarding directionality of the HAM because it was no
longer a uniform dose distribution.
Although other centers have advocated IOERT (2, 9,
10), this technique is not always feasible in certain sites
owing to anatomic limitations (3, 8). Moreover, IOERT
does not allow ‘‘DP’’ in the same manner achieved by
HDR-IORT using the HAM applicator.
Harrison et al. (4) initially described our results using
the HAM applicator to deliver HDR-IORT in 1995. In
our experience, this flexible applicator is more advanta-
geous because it can be molded to the tumor bed and allows
more conformal treatment on curved surfaces. Moreover,
Fig. 5. Dose distribution of high-dose-rate intraoperative radiation therapy with dose painting used for dose escalation (a) and irregular field (b).
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the applicator is low. Lead shields and wet lap pads are
often used to protect and displace normal organs from the
target area to reduce the dose to the radiosensitive organs
and structures in the pelvis. Nevertheless, complications
such as ureteral stenosis, bowel obstruction, and neuropathy
have been previously reported (11); thus lead shields and
lap pads may not be sufficient to protect adjacent highly
radiosensitive structures, and the use of the HAM appli-
cator for dose de-escalation should be encouraged to avoid
high doses to areas at higher risk of complication.
The potential for severe late complications related to
a single high dose remains a concern (8, 12) because the
classic principles of radiobiology, sublethal damage repair,
reoxygenation of hypoxic cells, and redistribution of cells
in the cell cycle are not exploited. Haddock et al. (2) re-
ported in reirradiated patients with colorectal cancer using
IOERT that doses exceeding 12.5 Gy in a single fraction
were associated with increased incidence and severity of
neuropathy. Other common IOERT-related complications
included wound infection, gastrointestinal tract fistula,
and ureteral obstruction. A recent review from Australia
(13) concluded that IORT adds a benefit for LC in all
common cancers when used in the multimodal treatment;
however, IORT may not improve OS and has significant
morbidity depending on the tumor site. In our series, all
patients were treated with doses from a minimum of
15 Gy up to 18.5 Gy and no neuropathy was observed.
Three patients (19%) had Grade 3 complication as reported
by the physician during followup visit: one had urethral
stenosis and two others had fistulas (rectovaginal and
ureter). Nonetheless, it is not easy to separate treatment-
related local complications in patients with recurrent
tumors previously treated with surgery and radiationtherapy. Previously published data from our institution
described the most common type of toxicity: wound
(24%), ureter (23%), and bladder (20%) complication in
patients with recurrent colorectal cancer who received
HDR-IORT without DP (14).
Despite the use of HDR-IORT, local failure can occur in
up to 50% of patients (2, 8). Resection margin status has
been shown to be the primary predictor of local failure.
In a prior study from our institution, patients with R1 or
R2 resections had a median time to local failure of 38 vs.
63 months for patients with an R0 resection (15). Although
negative margins can be obtained microscopically in
a second radical resection, in previously irradiated patients,
clear margins are difficult to achieve even by the most
experienced surgeons in high-volume cancer centers. The
cohort of patients receiving IORT-HDR-DP was particu-
larly high risk for positive margins as all patients had recur-
rent disease and previous EBRT. Yet, despite positive
microscopic margins in 25% of our patients, the 2-year
LC was excellent (80%), suggesting that IORT was effec-
tive as an adjuvant treatment. Given the small cohort of
patients and its retrospective nature, we cannot draw defin-
itive conclusions related to survival outcomes. Also, owing
to the lack of a control group, we cannot evaluate the real
impact of HDR-IORT-DP in LC compared with regular
HDR-IORT without DP.
The largest single-institution experience in IOERT on
recurrent colorectal cancer (n5 607) from the Mayo Clinic
showed a 3-year local and distant relapse incidence of 23%
and 49%, respectively (2). In their series, 37% of the resec-
tions were R1. Interestingly, despite comparable LC rates to
the Mayo Clinic series, the DM rate (69%) was higher in
our cohort, potentially demonstrating more advanced
disease at the time of surgery or more aggressive tumor
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Fig. 6. (a) 2-Year actuarial OS and (b) 2-year actuarial LC. OS5 overall
survival; LC5 local control.
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sites in addition to colorectal cancers.
Local recurrence after previous EBRT also seems to be
an unfavorable factor. The Mayo Clinic series reported 5-
year survival of 20% in patients with recurrent colorectal
cancer without prior radiation vs. 12% in previously irradi-
ated patients (16). In our study of previously irradiated
patients, the 2-year actuarial OS was 20%. DM was the
major problem in our series because about two-thirds of
the patients developed DM and died of disease. This high-
lights the difficulty of achieving systemic tumor control
despite aggressive local therapy using radical resection
followed by HDR-IORT-DP to sterilize the tumor bed. Ulti-
mately, with the introduction of better systemic therapies,
the role of improved local therapy will be even more
critical (7, 8, 11). Enhancing our ability to deliver effective
intraoperative radiotherapy and reducing the impact of this
focal high-dose radiotherapy on adjacent structures
increases the therapeutic benefit of these approaches for
our patients. Prospective studies are needed to furtherevaluate the benefit of IORT in the setting of radical resec-
tions and to determine the long-term effects of this therapy
on quality of life for patients undergoing these procedures.Conclusions
IORT does have a role in the multidisciplinary manage-
ment of locally advanced or recurrent tumors and should be
considered as an adjuvant treatment to surgery. The use of
HDR-IORT-DP technique seems to be feasible and safe in
patients with locally advanced or recurrent previously irra-
diated tumors. HDR-IORT-DP may allow for additional
dose escalation in this unfavorable group of patients;
further studies are warranted to evaluate efficacy of this
approach in a larger patient cohort. Although LC was
encouraging in this high-risk group, further improvement
is needed in the management of DM disease. Advances in
systemic treatments including more effective chemotherapy
and/or new molecular target agents may address this issue.
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